Pharmacokinetics and Blood Pressure Response of Losartan in End-Stage Renal Disease

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.38, Iss.6, 2000-06, pp. : 519-526

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics of Rosiglitazone in Patients with End-stage Renal Disease

By Thompson-Culkin K Zussman B Miller AK Freed MI

The Journal of International Medical Research, Vol. 30, Iss. 4, 2002-07 ,pp. : 391-399

Field House Publishing

Access to resources Recommend Favorite

Epidemiology of end-stage renal disease

By Roderick Paul

Clinical Medicine, Vol. 2, Iss. 3, 2002-05 ,pp. : 200-204

Royal College Of Physicians

Access to resources Recommend Favorite

The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy

By Carides George W.

PharmacoEconomics, Vol. 24, Iss. 6, 2006-01 ,pp. : 549-558

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of remifentanil in end-stage renal failure

Inpharma, Vol. 1, Iss. 1341, 2002-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

The pharmacokinetics (PK) of aprepitant are not affected in patients with end-stage renal disease (ESRD) or severe renal impairment

Inpharma, Vol. 1, Iss. 1494, 2005-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite